| Bioactivity | SR-4835 is a potent, highly selective and ATP competitive dual inhibitor of CDK12/CDK13 (CDK12: IC50=99 nM, Kd=98 nM; CDK13: Kd=4.9 nM). SR-4835 acts in synergy with DNA-damaging chemotherapy and PARP inhibitors and provokes triple-negative breast cancer (TNBC) cell death[1]. | ||||||||||||
| Invitro | SR-4835 (90 nM; 0.5-48 hours) suppresses ATM and RAD51 protein levels[1]. SR-4835 inhibits CDK12/CDK13 which triggers intronic polyadenylation site cleavage and suppresses the expression of core DNA damage response proteins[1]. Western Blot Analysis[1] Cell Line: | ||||||||||||
| Name | SR-4835 | ||||||||||||
| CAS | 2387704-62-1 | ||||||||||||
| Formula | C21H20Cl2N10O | ||||||||||||
| Molar Mass | 499.36 | ||||||||||||
| Transport | Room temperature in continental US; may vary elsewhere. | ||||||||||||
| Storage |
|
SR-4835
CAS: 2387704-62-1 F: C21H20Cl2N10O W: 499.36
SR-4835 is a potent, highly selective and ATP competitive dual inhibitor of CDK12/CDK13 (CDK12: IC50=99 nM, Kd=98 nM; CD
Sales Email：peptidedb@qq.com
This product is for research use only, not for human use. We do not sell to patients.